drugset / Trial / NCT01510899

A Study on the Effect of Renal Impairment on the Pharmacokinetics of RO4917838

NCT01510899

Phase 1 Completed 12 enrolled Hoffmann-La Roche
Non-randomizedParallel-groupOpen-label

Summary

This open-label, single-dose, parallel-group study will investigate the pharmacokinetics and safety of RO4917838 in healthy and renal impaired subjects. Subjects will receive a single dose of RO4917838.

Timeline

Start
2011-10
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject bitopertin Small molecule

Indications

No indication recorded.